Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2012

View Archived Issues

ISU Abxis reports on phase II program for Fabry's disease

PDS Biotechnology and Merck KGaA enter new license agreement

Data reported from five clinical studies of panobinostat

Capricor clear to advance clinical testing of stem cell therapy for myocardial regeneration

Novel potential Gaucher's disease drugs designed in U.S.

Investigators in China develop new candidate cognition-enhancing drugs

GSK patents novel inhibitors of LDL-PLA2

Research in Shanghai yields new c-Met inhibitors

Alchemia demerges oncology business

Rhizen Pharmaceuticals presents novel candidate steatohepatitis/diabetes drugs

Japanese approval sought for subcutaneous arthritis drug

Ligand Pharmaceuticals divulges new results on LGD-6972

Zalicus kicks off multiple-ascending-dose Z-944 study

OncoVista obtains IND clearance for solid tumor therapy

Galenea enters neuroscience collaboration

FDA accepts resubmitted raxibacumab BLA

Shionogi-ViiV Healthcare discloses initial data from SINGLE trial

CYT-017 obtains orphan drug status

Ohr Pharmaceutical reports encouraging preclinical data on squalamine eye drop

Inotuzumab ozogamicin shows promise in NHL and ALL

BioInvent announces topline results from GLACIER trial

FDA grants orphan drug status to cell therapy for Hurler's syndrome

Cangene discontinues program

TD-1211 trial meets primary endpoint

Viralytics initiates extension of CALM trial

Nymox provides update on phase III NX-1207 study

Research in Taiwan reveals new potential target for ovarian cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...